Estrella Immunopharma (ESLA)
Develops ARTEMIS T-cell therapies for B-cell malignancies.
Something off on this page? Send us feedback.
Develops ARTEMIS T-cell therapies targeting CD19 and CD22 for B-cell malignancies. EB103 is in dose expansion in the STARLIGHT-1 study, while EB104 is a dual-targeting program.
Develops ARTEMIS T-cell therapies targeting CD19 and CD22 for B-cell malignancies. Its lead candidate, EB103, is in dose expansion in the STARLIGHT-1 Phase I/II study, while EB104 is a dual CD19/CD22-targeting program. The company also works with Imugene on a solid-tumor approach combining EB103 with CF33-CD19t.
Formed from Eureka Therapeutics assets, it holds an exclusive license for the ARTEMIS platform and relies on Eureka for defined STARLIGHT-1 clinical-trial services. Enrollment has continued in the United States. The business remains centered on clinical development, with its platform license, trial-services arrangement, and Imugene collaboration shaping execution.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $146.7K · Total debt $0 · Total assets $1.8M · Shareholders' equity −$7.4M
- Revenue
- $0
- Operating income
- −$2.1M
- Net income
- −$2.3M
No dividends on record.
| Institutions16 holders · as of Mar 31, 2026 | 11.91% | 5.18M shares | |
| Insiders2 holders · as of Aug 26, 2026 | 1.79% | 779.6K shares | |
| Otherremainder | 86.30% | 37.54M shares |
43.50M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCInstitution | 9.42% | 4.10M | 13Fas of Mar 31, 2026 |
Cheng LiuInsiderdirector, officer: CEO | 0.91% | 397,437 | Form 4filed Aug 26, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 0.88% | 382,469 | 13Fas of Mar 31, 2026 |
Jiandong XuInsiderofficer: Chief Financial Officer | 0.88% | 382,188 | Form 4filed Aug 25, 2026 ↗ |
Wells Fargo & Company/MNInstitution | 0.61% | 264,388 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 22, 2025 | Jiandong Xu | officer: Chief Financial Officer | +1,000 | $1.16 |
| Sep 11, 2025 | Jiandong Xu | officer: Chief Financial Officer | +100 | $1.04 |
| Oct 7, 2025 | Jiandong Xu | officer: Chief Financial Officer | +1,000 | $1.33 |
- Gilead Sciences
CD19 CAR-T leader in relapsed/refractory large B-cell lymphoma
- Bristol-Myers Squibb
CD19 CAR-T supplier across relapsed/refractory B-cell malignancies
- Novartis (ADR)
CD19 CAR-T supplier for relapsed/refractory lymphoma and ALL
- ADC Therapeutics
CD19-targeted therapy supplier in relapsed/refractory DLBCL
- Cellectis (ADR)
Allogeneic dual-target CAR-T developer in relapsed/refractory B-NHL
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Estrella Immunopharma | $0.6900 | −0.22% | $29.4M | — | — | — | — |
| Gilead Sciences | $149.00 | −0.41% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Bristol-Myers Squibb | $67.88 | +0.34% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Novartis (ADR) | $162.04 | −0.25% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| ADC Therapeutics | $1.31 | −1.12% | $167.9M | — | — | 2.1 | +2.2% |
| Cellectis (ADR) | $3.26 | −1.51% | $326.4M | — | — | 4.2 | −59.2% |
| Median | 19.7 | 16.5 | 4.2 | +2.2% |